Cediranib maleate (BioDeep_00000657266)
代谢物信息卡片
Cediranib (maleate)
化学式: C29H31FN4O7 (566.2176668)
中文名称: 西地尼布马来酸盐
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NC4=CC(=C(C=C43)OC)OCCCN5CCCC5.C(=CC(=O)O)C(=O)O
InChI: 2-1-
描述信息
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors
C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor
D000970 - Antineoplastic Agents
同义名列表
2 个代谢物同义名
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Stephan Ursprung, Helen Mossop, Ferdia A Gallagher, Evis Sala, Richard Skells, Jamal A N Sipple, Thomas J Mitchell, Anita Chhabra, Kate Fife, Athena Matakidou, Gemma Young, Amanda Walker, Martin G Thomas, Mireia Crispin Ortuzar, Mark Sullivan, Andrew Protheroe, Grenville Oades, Balaji Venugopal, Anne Y Warren, John Stone, Tim Eisen, James Wason, Sarah J Welsh, Grant D Stewart. The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer - a study protocol.
BMC cancer.
2021 Nov; 21(1):1238. doi:
10.1186/s12885-021-08965-4. [PMID: 34794412] - Peter E Hall, Scott T C Shepherd, Janet Brown, James Larkin, Robert Jones, Christy Ralph, Robert Hawkins, Simon Chowdhury, Ekaterini Boleti, Amit Bahl, Kate Fife, Andrew Webb, Simon J Crabb, Thomas Geldart, Robert Hill, Joanna Dunlop, Duncan McLaren, Charlotte Ackerman, Akhila Wimalasingham, Luis Beltran, Paul Nathan, Thomas Powles. Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted Therapy.
European urology focus.
2020 09; 6(5):999-1005. doi:
10.1016/j.euf.2019.01.010. [PMID: 30738795] - Chloe J Peach, Laura E Kilpatrick, Jeanette Woolard, Stephen J Hill. Comparison of the ligand-binding properties of fluorescent VEGF-A isoforms to VEGF receptor 2 in living cells and membrane preparations using NanoBRET.
British journal of pharmacology.
2019 09; 176(17):3220-3235. doi:
10.1111/bph.14755. [PMID: 31162634] - Cong Zhou, Sarah Taylor, Jonathan Tugwood, Kathryn Simpson, Gordon C Jayson, Paul Symonds, James Paul, Susan Davidson, Karen Carty, Elaine McCartney, Debbie Rai, Caroline Dive, Catharine West. Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients.
British journal of clinical pharmacology.
2019 08; 85(8):1781-1789. doi:
10.1111/bcp.13965. [PMID: 30980733] - F E Marti Marti, G C Jayson, P Manoharan, J O'Connor, A G Renehan, A C Backen, H Mistry, F Ortega, K Li, K L Simpson, J Allen, J Connell, S Underhill, V Misra, K J Williams, I Stratford, A Jackson, C Dive, M P Saunders. Novel phase I trial design to evaluate the addition of cediranib or selumetinib to preoperative chemoradiotherapy for locally advanced rectal cancer: the DREAMtherapy trial.
European journal of cancer (Oxford, England : 1990).
2019 08; 117(?):48-59. doi:
10.1016/j.ejca.2019.04.029. [PMID: 31229949] - Meinan Yu, Dunyan Su, Yuanyuan Yang, Lin Qin, Chuan Hu, Rui Liu, Yang Zhou, Chuanyao Yang, Xiaotong Yang, Guanlin Wang, Huile Gao. D-T7 Peptide-Modified PEGylated Bilirubin Nanoparticles Loaded with Cediranib and Paclitaxel for Antiangiogenesis and Chemotherapy of Glioma.
ACS applied materials & interfaces.
2019 Jan; 11(1):176-186. doi:
10.1021/acsami.8b16219. [PMID: 30525386] - Alison C Backen, Andre Lopes, Harpreet Wasan, Daniel H Palmer, Marian Duggan, David Cunningham, Alan Anthoney, Pippa G Corrie, Srinivasan Madhusudan, Anthony Maraveyas, Paul J Ross, Justin S Waters, William P Steward, Charlotte Rees, Mairéad G McNamara, Sandy Beare, John A Bridgewater, Caroline Dive, Juan W Valle. Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial.
British journal of cancer.
2018 07; 119(1):27-35. doi:
10.1038/s41416-018-0132-8. [PMID: 29925934] - Milan Grkovski, Sally-Ann Emmas, Sean D Carlin. 18F-Fluoromisonidazole Kinetic Modeling for Characterization of Tumor Perfusion and Hypoxia in Response to Antiangiogenic Therapy.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
2017 10; 58(10):1567-1573. doi:
10.2967/jnumed.117.190892. [PMID: 28360207] - Jianguo Li, Nidal Al-Huniti, Anja Henningsson, Weifeng Tang, Eric Masson. Population pharmacokinetic and exposure simulation analysis for cediranib (AZD2171) in pooled Phase I/II studies in patients with cancer.
British journal of clinical pharmacology.
2017 08; 83(8):1723-1733. doi:
10.1111/bcp.13266. [PMID: 28213941] - Weifeng Tang, Alex McCormick, Jianguo Li, Eric Masson. Clinical Pharmacokinetics and Pharmacodynamics of Cediranib.
Clinical pharmacokinetics.
2017 07; 56(7):689-702. doi:
10.1007/s40262-016-0488-y. [PMID: 27943222] - Jung-Min Lee, Ashley Cimino-Mathews, Cody J Peer, Alexandra Zimmer, Stanley Lipkowitz, Christina M Annunziata, Liang Cao, Maria I Harrell, Elizabeth M Swisher, Nicole Houston, Dana-Adriana Botesteanu, Janis M Taube, Elizabeth Thompson, Aleksandra Ogurtsova, Haiying Xu, Jeffers Nguyen, Tony W Ho, William D Figg, Elise C Kohn. Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2017 Jul; 35(19):2193-2202. doi:
10.1200/jco.2016.72.1340. [PMID: 28471727] - Mihaela Rata, David J Collins, James Darcy, Christina Messiou, Nina Tunariu, Nandita Desouza, Helen Young, Martin O Leach, Matthew R Orton. Assessment of repeatability and treatment response in early phase clinical trials using DCE-MRI: comparison of parametric analysis using MR- and CT-derived arterial input functions.
European radiology.
2016 Jul; 26(7):1991-8. doi:
10.1007/s00330-015-4012-9. [PMID: 26385804] - Shweta Takyar, Jose Diaz, Manu Sehgal, Francisco Sapunar, Hardev Pandha. First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
Anti-cancer drugs.
2016 Jun; 27(5):383-97. doi:
10.1097/cad.0000000000000335. [PMID: 26886011] - Christina L Addison, Keyue Ding, Lesley Seymour, Huijun Zhao, Scott A Laurie, Frances A Shepherd, Glenwood D Goss, Penelope A Bradbury. Analysis of serum protein levels of angiogenic factors and their soluble receptors as markers of response to cediranib in the NCIC CTG BR.24 clinical trial.
Lung cancer (Amsterdam, Netherlands).
2015 Nov; 90(2):288-95. doi:
10.1016/j.lungcan.2015.09.004. [PMID: 26415995] - Jair Bar, Keyue Ding, Huijun Zhao, Lei Han, Scott A Laurie, Lesley Seymour, Christina L Addison, Frances A Shepherd, Glenwood D Goss, Jim Dimitroulakos, Penelope A Bradbury. Angiotensin-Converting Enzyme and Aldosterone Serum Levels as Prognostic and Predictive Biomarkers for Cediranib in NCIC Clinical Trials Group Study BR.24.
Clinical lung cancer.
2015 Nov; 16(6):e189-201. doi:
10.1016/j.cllc.2015.05.002. [PMID: 26081815] - Elizabeth R Gerstner, Xiaobu Ye, Dan G Duda, Michael A Levine, Tom Mikkelsen, Thomas J Kaley, Jeffrey J Olson, Burt L Nabors, Manmeet S Ahluwalia, Patrick Y Wen, Rakesh K Jain, Tracy T Batchelor, Stuart Grossman. A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma.
Neuro-oncology.
2015 Oct; 17(10):1386-92. doi:
10.1093/neuonc/nov085. [PMID: 26008604] - Mark W Kieran, Susan Chi, Stewart Goldman, Arzu Onar-Thomas, Tina Young Poussaint, Sridhar Vajapeyam, Frederic Fahey, Shengjie Wu, David C Turner, Clinton F Stewart, Marsha Moses, Roger J Packer, Regina Jakacki, Anu Banerjee, James M Boyett, Maryam Fouladi, Larry Kun. A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors.
Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery.
2015 Sep; 31(9):1433-45. doi:
10.1007/s00381-015-2812-5. [PMID: 26188774] - Fang Liu, Li Wang, Xian-Xia Zhang, Shu-Yun Min, Yi-Xuan Liu, Zhi Zuo, Zhi-Xing Jin, Zhi-Ling Zhu. Vascular endothelial growth factor receptor-2 inhibitor cediranib causes regression of endometriotic lesions in a rat model.
International journal of clinical and experimental pathology.
2015; 8(2):1165-74. doi:
NULL. [PMID: 25973002] - A J C Pommier, R Shaw, S K M Spencer, S R Morgan, P M Hoff, J D Robertson, S T Barry, J M Jürgensmeier. Serum protein profiling reveals baseline and pharmacodynamic biomarker signatures associated with clinical outcome in mCRC patients treated with chemotherapy ± cediranib.
British journal of cancer.
2014 Oct; 111(8):1590-604. doi:
10.1038/bjc.2014.436. [PMID: 25121956] - Husain K Khambati, Toni K Choueiri, Christian K Kollmannsberger, Scott North, George A Bjarnason, Ulka N Vaishampayan, Lori Wood, Jennifer J Knox, Min-Han Tan, Mary J MacKenzie, Frede Donskov, Brian I Rini, Daniel Y C Heng. Efficacy of targeted therapy for metastatic renal cell carcinoma in the elderly patient population.
Clinical genitourinary cancer.
2014 Oct; 12(5):354-8. doi:
10.1016/j.clgc.2014.02.009. [PMID: 24819320] - Anna Spreafico, Kim N Chi, Srikala S Sridhar, David C Smith, Michael A Carducci, Peter Kavsak, Tracy S Wong, Lisa Wang, S Percy Ivy, Som Dave Mukherjee, Christian K Kollmannsberger, Mahadeo A Sukhai, Naoko Takebe, Suzanne Kamel-Reid, Lillian L Siu, Sebastien J Hotte. A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients.
Investigational new drugs.
2014 Oct; 32(5):1005-16. doi:
10.1007/s10637-014-0106-5. [PMID: 24788563] - Marijo Bilusic, Yu-Ning Wong. Anti-angiogenesis in prostate cancer: knocked down but not out.
Asian journal of andrology.
2014 May; 16(3):372-7. doi:
10.4103/1008-682x.125903. [PMID: 24759579] - Tianli Wang, Kyle Baron, Wei Zhong, Richard Brundage, William Elmquist. Bayesian approach to estimate AUC, partition coefficient and drug targeting index for studies with serial sacrifice design.
Pharmaceutical research.
2014 Mar; 31(3):649-59. doi:
10.1007/s11095-013-1187-0. [PMID: 24092052] - Jair Bar, Stuart Spencer, Shethah Morgan, Laura Brooks, David Cunningham, Jane Robertson, Juliane M Jürgensmeier, Glenwood D Goss. Correlation of lactate dehydrogenase isoenzyme profile with outcome in patients with advanced colorectal cancer treated with chemotherapy and bevacizumab or cediranib: Retrospective analysis of the HORIZON I study.
Clinical colorectal cancer.
2014 Mar; 13(1):46-53. doi:
10.1016/j.clcc.2013.11.002. [PMID: 24355210] - S K M Spencer, A J C Pommier, S R Morgan, S T Barry, J D Robertson, P M Hoff, J M Jürgensmeier. Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy.
British journal of cancer.
2013 Nov; 109(11):2765-73. doi:
10.1038/bjc.2013.649. [PMID: 24149180] - Tracy T Batchelor, Elizabeth R Gerstner, Kyrre E Emblem, Dan G Duda, Jayashree Kalpathy-Cramer, Matija Snuderl, Marek Ancukiewicz, Pavlina Polaskova, Marco C Pinho, Dominique Jennings, Scott R Plotkin, Andrew S Chi, April F Eichler, Jorg Dietrich, Fred H Hochberg, Christine Lu-Emerson, A John Iafrate, S Percy Ivy, Bruce R Rosen, Jay S Loeffler, Patrick Y Wen, A Greg Sorensen, Rakesh K Jain. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.
Proceedings of the National Academy of Sciences of the United States of America.
2013 Nov; 110(47):19059-64. doi:
10.1073/pnas.1318022110. [PMID: 24190997] - N S Vasudev, V Goh, J K Juttla, V L Thompson, J M G Larkin, M Gore, P D Nathan, A R Reynolds. Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy.
British journal of cancer.
2013 Sep; 109(5):1230-42. doi:
10.1038/bjc.2013.429. [PMID: 23922108] - S Sahebjam, P L Bedard, V Castonguay, Z Chen, M Reedijk, G Liu, B Cohen, W-J Zhang, B Clarke, T Zhang, S Kamel-Reid, H Chen, S P Ivy, A R A Razak, A M Oza, E X Chen, H W Hirte, A McGarrity, L Wang, L L Siu, S J Hotte. A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503).
British journal of cancer.
2013 Aug; 109(4):943-9. doi:
10.1038/bjc.2013.380. [PMID: 23868004] - Srikala S Sridhar, Mary J Mackenzie, Sebastien J Hotte, Som D Mukherjee, Ian F Tannock, Nevin Murray, Christian Kollmannsberger, Masoom A Haider, Eric X Chen, Robert Halford, Lisa Wang, S Percy Ivy, Malcolm J Moore. A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium.
Investigational new drugs.
2013 Aug; 31(4):1008-15. doi:
10.1007/s10637-013-9931-1. [PMID: 23354849] - J M Jürgensmeier, H-J Schmoll, J D Robertson, L Brooks, M Taboada, S R Morgan, D Wilson, P M Hoff. Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy.
British journal of cancer.
2013 Apr; 108(6):1316-23. doi:
10.1038/bjc.2013.79. [PMID: 23449351] - Andrew X Zhu, Marek Ancukiewicz, Jeffrey G Supko, Dushyant V Sahani, Lawrence S Blaszkowsky, Jeffrey A Meyerhardt, Thomas A Abrams, Nadine Jackson McCleary, Pankaj Bhargava, Alona Muzikansky, Susan Sheehan, Eileen Regan, Eamala Vasudev, Michelle Knowles, Charles S Fuchs, David P Ryan, Rakesh K Jain, Dan G Duda. Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2013 Mar; 19(6):1557-66. doi:
10.1158/1078-0432.ccr-12-3041. [PMID: 23362324] - Christina Messiou, Matthew Orton, Joo Ern Ang, David J Collins, Veronica A Morgan, Dorothy Mears, Isabel Castellano, Dionysis Papadatos-Pastos, Andre Brunetto, Nina Tunariu, Helen Mann, Jean Tessier, Helen Young, Dana Ghiorghiu, Sarah Marley, Stan B Kaye, Johann S deBono, Martin O Leach, Nandita M deSouza. Advanced solid tumors treated with cediranib: comparison of dynamic contrast-enhanced MR imaging and CT as markers of vascular activity.
Radiology.
2012 Nov; 265(2):426-36. doi:
10.1148/radiol.12112565. [PMID: 22891356] - Jake S Burrell, Simon Walker-Samuel, Lauren C J Baker, Jessica K R Boult, Yann Jamin, Anderson J Ryan, John C Waterton, Jane Halliday, Simon P Robinson. Evaluation of novel combined carbogen USPIO (CUSPIO) imaging biomarkers in assessing the antiangiogenic effects of cediranib (AZD2171) in rat C6 gliomas.
International journal of cancer.
2012 Oct; 131(8):1854-62. doi:
10.1002/ijc.27460. [PMID: 22290271] - Nicholas P Campbell, Rangesh Kunnavakkam, Natasha Leighl, Mark D Vincent, David R Gandara, Marianna Koczywas, Barbara J Gitlitz, Edem Agamah, Sachdev P Thomas, Walter M Stadler, Everett E Vokes, Hedy L Kindler. Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium.
Lung cancer (Amsterdam, Netherlands).
2012 Oct; 78(1):76-80. doi:
10.1016/j.lungcan.2012.06.011. [PMID: 22831987] - Marina Sahade, Fernanda Caparelli, Paulo M Hoff. Cediranib: a VEGF receptor tyrosine kinase inhibitor.
Future oncology (London, England).
2012 Jul; 8(7):775-81. doi:
10.2217/fon.12.73. [PMID: 22830398] - Tianli Wang, Sagar Agarwal, William F Elmquist. Brain distribution of cediranib is limited by active efflux at the blood-brain barrier.
The Journal of pharmacology and experimental therapeutics.
2012 May; 341(2):386-95. doi:
10.1124/jpet.111.190488. [PMID: 22323823] - Rolf W Sparidans, Selvi Durmus, Ning Xu, Alfred H Schinkel, Jan H M Schellens, Jos H Beijnen. Liquid chromatography-tandem mass spectrometric assay for the VEGFR inhibitor cediranib and its primary human metabolite cediranib-N⁺-glucuronide in plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2012 May; 895-896(?):169-73. doi:
10.1016/j.jchromb.2012.03.020. [PMID: 22476055] - Peter Mulders, Robert Hawkins, Paul Nathan, Igle de Jong, Susanne Osanto, Emilio Porfiri, Andrew Protheroe, Carla M L van Herpen, Bijoyesh Mookerjee, Laura Pike, Juliane M Jürgensmeier, Martin E Gore. Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study.
European journal of cancer (Oxford, England : 1990).
2012 Mar; 48(4):527-37. doi:
10.1016/j.ejca.2011.12.022. [PMID: 22285180] - Tianli Wang, Rajneet K Oberoi, William F Elmquist. Determination of cediranib in mouse plasma and brain tissue using high-performance liquid chromatography-mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2011 Dec; 879(32):3812-7. doi:
10.1016/j.jchromb.2011.10.025. [PMID: 22127272] - Claire L Mitchell, J P B O'Connor, C Roberts, Y Watson, A Jackson, S Cheung, J Evans, J Spicer, A Harris, C Kelly, S Rudman, M Middleton, A Fielding, J Tessier, H Young, G J M Parker, G C Jayson. A two-part phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics.
Cancer chemotherapy and pharmacology.
2011 Sep; 68(3):631-41. doi:
10.1007/s00280-010-1534-3. [PMID: 21120480] - Elizabeth Fox, Richard Aplenc, Rochelle Bagatell, Meredith K Chuk, Eva Dombi, Wendy Goodspeed, Anne Goodwin, Marie Kromplewski, Nalini Jayaprakash, Marcelo Marotti, Kathryn H Brown, Barbara Wenrich, Peter C Adamson, Brigitte C Widemann, Frank M Balis. A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2010 Dec; 28(35):5174-81. doi:
10.1200/jco.2010.30.9674. [PMID: 21060028] - Tracy T Batchelor, Dan G Duda, Emmanuelle di Tomaso, Marek Ancukiewicz, Scott R Plotkin, Elizabeth Gerstner, April F Eichler, Jan Drappatz, Fred H Hochberg, Thomas Benner, David N Louis, Kenneth S Cohen, Houng Chea, Alexis Exarhopoulos, Jay S Loeffler, Marsha A Moses, Percy Ivy, A Gregory Sorensen, Patrick Y Wen, Rakesh K Jain. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2010 Jun; 28(17):2817-23. doi:
10.1200/jco.2009.26.3988. [PMID: 20458050] - Walter Fiedler, Rolf Mesters, Michael Heuser, Gerhard Ehninger, Wolfgang E Berdel, Ute Zirrgiebel, Jane D Robertson, Tom A Puchalski, Barbara Collins, Juliane M Jürgensmeier, Hubert Serve. An open-label, Phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia.
Leukemia research.
2010 Feb; 34(2):196-202. doi:
10.1016/j.leukres.2009.07.020. [PMID: 19674789] - Glenwood D Goss, Andrew Arnold, Frances A Shepherd, Mircea Dediu, Tudor-Eliade Ciuleanu, David Fenton, Mauro Zukin, David Walde, Francis Laberge, Mark D Vincent, Peter M Ellis, Scott A Laurie, Keyue Ding, Eliot Frymire, Isabelle Gauthier, Natasha B Leighl, Cheryl Ho, Jonathan Noble, Christopher W Lee, Lesley Seymour. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2010 Jan; 28(1):49-55. doi:
10.1200/jco.2009.22.9427. [PMID: 19917841] - Michael Medinger, Norbert Esser, Ute Zirrgiebel, Anderson Ryan, Juliane M Jürgensmeier, Joachim Drevs. Antitumor and antiangiogenic activity of cediranib in a preclinical model of renal cell carcinoma.
Anticancer research.
2009 Dec; 29(12):5065-76. doi:
NULL. [PMID: 20044618] - Walid S Kamoun, Carsten D Ley, Christian T Farrar, Annique M Duyverman, Johanna Lahdenranta, Delphine A Lacorre, Tracy T Batchelor, Emmanuelle di Tomaso, Dan G Duda, Lance L Munn, Dai Fukumura, A Gregory Sorensen, Rakesh K Jain. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2009 May; 27(15):2542-52. doi:
10.1200/jco.2008.19.9356. [PMID: 19332720] - Dietmar W Siemann, W D Brazelle, Juliane M Jürgensmeier. The vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor cediranib (Recentin; AZD2171) inhibits endothelial cell function and growth of human renal tumor xenografts.
International journal of radiation oncology, biology, physics.
2009 Mar; 73(3):897-903. doi:
10.1016/j.ijrobp.2008.10.031. [PMID: 19215823] - Eric Chen, Derek Jonker, Isabelle Gauthier, Martha MacLean, Julie Wells, Jean Powers, Lesley Seymour. Phase I study of cediranib in combination with oxaliplatin and infusional 5-Fluorouracil in patients with advanced colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2009 Feb; 15(4):1481-6. doi:
10.1158/1078-0432.ccr-08-0761. [PMID: 19228749] - Bhanu K Vakkalanka, Ronald M Bukowski. Novel drugs for renal cell carcinoma.
Expert opinion on investigational drugs.
2008 Oct; 17(10):1501-16. doi:
10.1517/13543784.17.10.1501. [PMID: 18808310] - D P Bradley, J L Tessier, D Checkley, H Kuribayashi, J C Waterton, J Kendrew, S R Wedge. Effects of AZD2171 and vandetanib (ZD6474, Zactima) on haemodynamic variables in an SW620 human colon tumour model: an investigation using dynamic contrast-enhanced MRI and the rapid clearance blood pool contrast agent, P792 (gadomelitol).
NMR in biomedicine.
2008 Jan; 21(1):42-52. doi:
10.1002/nbm.1161. [PMID: 17458919] - Charles J Ryan, Walter M Stadler, Bruce Roth, Douglass Hutcheon, Shauna Conry, Thomas Puchalski, Charles Morris, Eric J Small. Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC).
Investigational new drugs.
2007 Oct; 25(5):445-51. doi:
10.1007/s10637-007-9050-y. [PMID: 17458505] - Joachim Drevs, Patrizia Siegert, Michael Medinger, Klaus Mross, Ralph Strecker, Ute Zirrgiebel, Jan Harder, Hubert Blum, Jane Robertson, Juliane M Jürgensmeier, Thomas A Puchalski, Helen Young, Owain Saunders, Clemens Unger. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2007 Jul; 25(21):3045-54. doi:
10.1200/jco.2006.07.2066. [PMID: 17634482]